MGNX (Macrogenics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGNX Macrogenics Inc MGNX
49 GF Score
Price $3.98
GF Value $4.09
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Macrogenics FFO per Share?

FFO per Share only applies to REITs.

MGNX
49GF Score
Macrogenics Inc MGNX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Macrogenics (MGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be undervalued. The current stock price of $3.98 is trading 2.7% below its estimated GF Value™ of $4.09. GuruFocus considers Macrogenics to be Fairly Valued.

Key valuation signals for MGNX:

  • FFO per Share:
  • GF Value™: $4.09 vs. price of $3.98 (2.7% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges M55:Germany
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
49GF Score

Get the complete analysis for MGNX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price
$4.09
GF Value